Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).
Mohamed E. Salem, MD
Advertisement
Articles by Mohamed E. Salem, MD
It is highly probable that molecular profiling is the key to more precise treatments, as well as prediction of outcomes in metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Salem on the Results of the MyPathway Trial in mCRCApril 2nd 2019
Tumor Location Insights in mCRC Challenge Standard of CareDecember 2nd 2016
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5